CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2019--
announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president
and chief executive officer, will provide a corporate update at the SVB
Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on
Thursday, February 28, 2019, in New York City.
A live webcast of the presentation can be accessed under “Event
Calendar” in the Investors & Media section of the Company’s website.
An archive copy of the webcast will be available on the Synlogic website
for approximately 30 days after the event.
Synlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer beneficial
microbes to perform or deliver critical functions missing or damaged due
to disease. Synthetic Biotic medicines are designed to act locally and
have a systemic effect to address disease in patients. Synlogic’s two
lead programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders, including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005878/en/
Source: Synlogic, Inc.
Elizabeth Wolffe, Ph.D.